We are excited to announce that our Principal, Ms. Pauli Wong, has been appointed as the Honorary IP Advisor by the Hong Kong Medical & Healthcare Device Industries Association (HKMHDIA) for the term 2025-2026. She will provide advice and guidance to support HKMHDIA’s mission in advocating for streamlined regulatory policies to position Hong Kong as a leader in medical technologies. 

Pauli has served many HKMHDIA members in the life sciences and medical devices sectors as their patent attorney over the past few years. She is eager to provide strategic guidance for the association, leveraging her deep understanding of intellectual property to help HKMHDIA members safeguard their innovations and enhance their competitive edge. 

We are confident that Pauli's expertise and dedication will greatly benefit HKMHDIA and its members, driving innovation and success in the life sciences and medical devices sector of Hong Kong. 

我們過去活動

Jennifer Che has been Recognized as IAM Global Leaders 2026

2025年11月4日

Eagle IP is Coming to San Francisco and Washington DC!

2025年10月15日

Jennifer Che has been listed on the IAM Strategy 300

2025年8月15日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

2025年7月3日

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

2025年6月12日

Recommended Insights

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

2021年10月19日
The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]
閱讀更多 >

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
閱讀更多 >

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

2021年12月6日
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
閱讀更多 >

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

2024年2月7日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]
閱讀更多 >
Top crossarrow-right